| 24.965 0.165 (0.67%) | 09-16 14:11 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.39 |
1-year : | 32.11 |
| Resists | First : | 26.02 |
Second : | 27.5 |
| Pivot price | 25.52  |
|||
| Supports | First : | 23.63 |
Second : | 19.66 |
| MAs | MA(5) : | 24.58 |
MA(20) : | 25.66 |
| MA(100) : | 20.91 |
MA(250) : | 21.47 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 31.7 |
D(3) : | 23.7 |
| RSI | RSI(14): 54.3 |
|||
| 52-week | High : | 34.72 | Low : | 15.96 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ZLAB ] has closed above bottom band by 41.4%. Bollinger Bands are 20.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.05 - 25.17 | 25.17 - 25.28 |
| Low: | 24.19 - 24.33 | 24.33 - 24.46 |
| Close: | 24.57 - 24.8 | 24.8 - 25.01 |
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
Tue, 15 Sep 2026
Zai Lab (ZLAB) Rebounds On A Fair Value Debate, Is It Still Below Fair Value? - simplywall.st
Mon, 14 Sep 2026
(ZLAB) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Thu, 10 Sep 2026
ZLAB - Finviz
Sun, 06 Sep 2026
Zai Lab (ZLAB) Stock Looks Stretched On Sales But Reasonable On Broader Checks - Yahoo Finance
Thu, 20 Aug 2026
Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)? - Yahoo Finance
Wed, 19 Aug 2026
Zai Lab: Revenue Growth And Zoci's Upside Optionality (NASDAQ:ZLAB) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 112 (M) |
| Shares Float | 97 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 38.4 (%) |
| Shares Short | 7,470 (K) |
| Shares Short P.Month | 6,350 (K) |
| EPS | -1.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.4 |
| Profit Margin | -41.9 % |
| Operating Margin | -72 % |
| Return on Assets (ttm) | -14.8 % |
| Return on Equity (ttm) | -27 % |
| Qtrly Rev. Growth | -3.3 % |
| Gross Profit (p.s.) | 0.15 |
| Sales Per Share | 4 |
| EBITDA (p.s.) | -2.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -133 (M) |
| Levered Free Cash Flow | -84 (M) |
| PE Ratio | -14.84 |
| PEG Ratio | 0 |
| Price to Book value | 4.66 |
| Price to Sales | 6.29 |
| Price to Cash Flow | -21.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|